Watch for preliminary data presentation at an upcoming medical society conference — positive efficacy/safety readout could be a major catalyst. Full 12-month follow-up data for all patients is the next key de-risking event. No financial data in this filing; next quarterly earnings will be critical for cash runway and revenue updates.
Price Chart
Executive Summary
Pulse Biosciences announced completion of patient enrollment (100 patients, doubled from original 50) in its PRECISE-BTN clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for symptomatic benign thyroid nodules, and that the first patient completed 12-month follow-up. This is a clinical milestone de-risking the path to potential FDA submission, but no efficacy or safety data have been released yet — the filing contains no financial figures, revenue, or guidance.
Key Facts
- Completed enrollment of 100 patients in PRECISE-BTN study (doubled from original 50-patient design)
- First patient enrolled completed final 12-month follow-up visit
- All 100 patients enrolled across 3 U.S. sites within ~12 months
- Preliminary data expected at upcoming medical conference; full data after all patients complete 12-month follow-up
- Study endpoints include safety, nodule volume reduction, symptomatic relief, hormone normalization, and quality of life
Financial Impact
No financial figures disclosed; clinical milestone de-risks regulatory pathway for a new indication in a large addressable market (benign thyroid nodules)
Risk Factors
- No efficacy or safety data released yet — enrollment completion does not guarantee positive outcomes
- Single-arm study design limits comparative evidence strength
- Regulatory pathway and timeline to FDA clearance remain uncertain
- Company is pre-revenue for this indication; cash burn rate and dilution risk are not addressed in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (PLSE) — Batch item 1 | 0001437749-26-030392 |
| Exhibit: ex_1009964.htm | 0001437749-26-030392 |
| Document: 0001437749-26-030392-index-headers.html | 0001437749-26-030392 |
| Document: 0001437749-26-030392-index.html | 0001437749-26-030392 |
| Document: 0001437749-26-030392.txt | 0001437749-26-030392 |
| 8-K Filing (PLSE) — Batch item 6 | 0001437749-26-030392 |
| Exhibit: ex_1009964.htm | 0001437749-26-030392 |
| Document: 0001437749-26-030392-index-headers.html | 0001437749-26-030392 |
| Document: 0001437749-26-030392-index.html | 0001437749-26-030392 |
| Document: 0001437749-26-030392.txt | 0001437749-26-030392 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $46.32 | awaiting T+60 | — | $52.66 (+13.69%) |
Oct 7, 2026 19d ago | 8-K | $49.09 | awaiting T+60 | — | $52.66 (+7.27%) |
Sep 15, 2026 5w ago | 8-K | $55.20 | awaiting T+60 | — | $52.66 (−4.60%) |
Aug 6, 2026 11w ago | 8-K | $42.41 | awaiting T+60 | — | $52.66 (−24.17%) |
Aug 6, 2026 11w ago | 424B5 | $42.41 | awaiting T+60 | — | $52.66 (−24.17%) |
Jul 29, 2026 12w ago | 8-K | $34.25 $52.68 | ▲ +53.81% | ▲ +49.08% | $52.66 (+53.75%) |
Jun 12, 2026 19w ago | Institutional Cluster | $24.37 $48.79 | ▲ +100.21% | ▲ +96.94% | $52.66 (+116.09%) |
Jun 10, 2026 19w ago | 8-K | $24.99 $54.71 | ▲ +118.93% | ▲ +112.35% | $52.66 (+110.72%) |
May 15, 2026 23w ago | Insider Cluster | $25.61 $43.32 | ▲ +69.15% | ▲ +64.30% | $52.66 (+105.62%) |
May 11, 2026 24w ago | Insider Cluster | $19.08 $37.90 | ▲ +98.64% | ▲ +94.24% | $52.66 (+176.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers